The CASP6 Knockout KYSE-30 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population featuring targeted disruption of the CASP6 gene (caspase-6) in the KYSE-30 human esophageal squamous cell carcinoma (ESCC) cell line. This polyclonal format provides a heterogeneous pool of gene-edited cells, enabling robust loss-of-function studies without clonal selection artifacts. The model is a versatile tool for investigating apoptotic signaling, drug resistance, and non-apoptotic roles of caspase-6 within a physiologically relevant cancer background.
KYSE-30 is a well-characterized ESCC cell line derived from a well-differentiated primary tumor, retaining epithelial morphology and molecular features typical of esophageal cancer. It is widely used to study carcinogenesis, apoptosis evasion, and chemoresistance. The cell line??s well-differentiated phenotype facilitates examination of differentiation-related pathways alongside apoptotic cascades, providing a consistent disease-relevant environment for interrogating caspase-6 functions.
CASP6 encodes executioner caspase-6, which cleaves substrates including LMNA, KRT18, PARP1, BID, and SATB1 to execute apoptosis. It is activated downstream of initiator caspases CASP8 and CASP9 and regulated by XIAP, FLIP, and BCL2 family proteins. Caspase-6 interacts with CASP3, XIAP, BIRC5/Survivin, DIABLO/SMAC, and HSP90. In the intrinsic pathway, cytochrome c/APAF1 activates CASP9, then CASP3 and CASP6. Beyond apoptosis, caspase-6 is involved in inflammation, neuronal development, and neurodegeneration (Alzheimer??s, Huntington??s, ALS). Thus, knockout abolishes substrate cleavage, blocking apoptosis and potentially altering non-apoptotic processes.
In KYSE-30 cells, eliminating caspase-6 disrupts both intrinsic and extrinsic apoptotic pathways, potentially imparting resistance to diverse death stimuli and mimicking cancer escape mechanisms. This facilitates dissection of caspase-6??s contribution to chemoresistance in ESCC and investigation of compensatory signaling, such as alternative cell death or survival pathways. The knockout also permits study of non-apoptotic roles in epithelial differentiation and inflammation relevant to ESCC pathogenesis, and identification of synthetic lethal interactions.
The cells are suited for Western blotting of cleaved caspase-6 and substrates (lamin A/C, KRT18), Annexin V assays, caspase activity measurements, cell viability (MTT/CTG), TUNEL, immunofluorescence, RNA-seq, and migration/invasion assays. Applications include apoptosis resistance mechanisms in ESCC, drug sensitivity profiling, intrinsic/extrinsic apoptosis signaling, and caspase-6??s non-canonical functions in cancer and neurodegeneration. Researchers can use this model for therapeutic screening and target validation in cell death pathways. For further information, please contact Ascent Research.
